Basilea announces agreement with Innoviva Specialty Therapeutics for the commercialization of antibiotic Zevtera (ceftobiprole) in the United States
Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, December 16,…
Rakovina Therapeutics Announces Closing of Oversubscribed $3M Private Placement
December 13, 2024 18:50 ET | Source: Rakovina Therapeutics Inc VANCOUVER, British…
Checkpoint Therapeutics Announces FDA Approval of UNLOXCYT(cosibelimab-ipdl)
WALTHAM, Mass., Dec. 13, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”)…
Rakovina Therapeutics Announces Closing of Oversubscribed $3M Private Placement
December 13, 2024 18:50 ET | Source: Rakovina Therapeutics Inc VANCOUVER, British…
Checkpoint Therapeutics Announces FDA Approval of UNLOXCYT(cosibelimab-ipdl)
WALTHAM, Mass., Dec. 13, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”)…
Actimed Therapeutics Announces Publication of Successful S-pindolol benzoate (ACM-001.1) Phase 1 Study in The Journal of Cachexia, Sarcopenia and Muscle
December 13, 2024 03:00 ET | Source: Actimed Therapeutics London, UK –…
Keros Therapeutics Announces Update on the Phase 2 TROPOS Trial
December 12, 2024 06:00 ET | Source: Keros Therapeutics, Inc. Keros will…
ProQR Therapeutics Announces $8.1 Million in New Funding from Rett Syndrome Research Trust to Expand RNA Editing Collaboration
LEIDEN, Netherlands & CAMBRIDGE, Mass., Dec. 11, 2024 (GLOBE NEWSWIRE) -- ProQR…
PureTech Founded Entity Seaport Therapeutics Presents Additional Data from Phase 1 Study of SPT-300 at ACNP Annual Meeting 2024
Multiple well-tolerated doses with pharmacodynamic activity were identified and will be included…
Seaport Therapeutics Presents Additional Data from Phase 1 Study of SPT-300 at ACNP Annual Meeting 2024
Multiple well-tolerated doses with pharmacodynamic activity were identified and will be included…